Cite
HARVARD Citation
van Vollenhoven, R. et al. (2014). FRI0267 A Prediction Model That Identifies Patients Most Likely to Benefit from First-Line Therapy with Adalimumab plus Methotrexate in Early Rheumatoid Arthritis. Annals of the rheumatic diseases. p. 480. [Online].